Image source: Unsplash/Louis Reed

IgM/IgG identification

Coronavirus antibody test in development

In response to the global COVID-19 pandemic, Beckman Coulter announced that it is developing assays to identify IgM and IgG antibodies to the coronavirus or SARS-CoV-2.

The assays will be designed for use on any of its high-throughput Access family of immunoassay systems, including the Access 2 and DxI series installed globally. Research has shown that after infection with SARS-CoV-2, viral antigens stimulate the body’s immune system to produce antibodies that can be detected with IgM and IgG tests. “Antibody assays play a critical role in understanding the measure of immunity an individual has developed against SARS-CoV-2,” said Kathleen Orland, senior vice president and general manager for Beckman Coulter’s chemistry and immunoassay business. “This type of understanding could help determine the identification of those who would require a vaccine once available or when an infected individual could safely return to work.”

This test could allow those without immunity to be identified and kept safe until the pandemic subsides

Shamiram R. Feinglass

“With the ability to assess a patient’s immunity to SARS-CoV-2, this testing modality may enable clinicians to clear hospital staff, emergency responders, and others to get back to work with an indication that have had prior exposure and therefore may have immunity to the disease,” said Shamiram R. Feinglass, M.D., MPH, chief medical officer, Beckman Coulter. “This test also could allow those without immunity to be identified and kept safe until the pandemic subsides.”

Once the assays are finalized, Beckman Coulter intends to follow FDA’s Emergency Use Notification process as provided in the FDA’s Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency (March 16, 2020). For the latest information on the new assays, visit www.beckmancoulter.com/coronavirus 


Source: Beckman Coulter

01.04.2020

Read all latest stories

Related articles

Photo

High-sensitivity troponin I assay

Speeding up diagnosis of myocardial infarction

The new generation troponin I assay unveiled by Beckman Coulter is helping improve heart attack diagnosis. Delivering high sensitivity, and rapid result turnaround times, every element of the Access…

Photo

Blood poisoning

Exploring the importance and challenges of early sepsis diagnosis

On the occasion of this year's World Sepsis Day, we spoke with Elena Sukhacheva, Ph.D., director of medical and scientific affairs at Beckman Coulter, about the status quo and outlook on sepsis…

Photo

Hematology

Early sepsis indicator helps identifying patients at risk

The critical element of testing for sepsis lies not so much in the location but in the timing and rapidity of results, according to Professor Jeannine T. Holden from Beckman Coulter Early…

Related products

Beckman Coulter – Access 2 Immunoassay System

Immunoassays

Beckman Coulter – Access 2 Immunoassay System

Beckman Coulter, Inc.
Beckman Coulter – Access Interleukin-6 (IL-6)

Immunoassays

Beckman Coulter – Access Interleukin-6 (IL-6)

Beckman Coulter, Inc.
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter, Inc.
Beckman Coulter – AU5800 Series

Clinical Chemistry

Beckman Coulter – AU5800 Series

Beckman Coulter, Inc.
Beckman Coulter – DxA 5000

Sample Processing

Beckman Coulter – DxA 5000

Beckman Coulter, Inc.